|
Tweet | ||
479 * ! | Wed, 8/12/2015, 8:30 AM - 10:20 AM | CC-3A | |
Recent Developments in Adaptive Designed Clinical Development Programs — Topic Contributed Papers | |||
Biopharmaceutical Section | |||
Organizer(s): James Bolognese, Cytel Inc. | |||
Chair(s): James Bolognese, Cytel Inc. | |||
8:35 AM | Optimizing Adaptive Design for Phase II Dose-Finding Trials Incorporating Long-Term Success and Financial Considerations — Narinder Nangia, AbbVie ; Jingjing Gao, AbbVie ; James Bolognese, Cytel Inc. ; Jaydeep Bhattacharyya, Cytel Inc. ; Nitin Patel, Cytel Inc. | ||
8:55 AM | Joint Optimization of Phase II and Phase III Designs When One or Two Doses Can Be Carried into Phase III — Nitin Patel, Cytel Inc. ; James Bolognese, Cytel Inc. ; Jaydeep Bhattacharyya, Cytel Inc. | ||
9:15 AM | Antiviral Treatments for Pandemic Influenza: A Bayesian Adaptive and Open Platform Randomized Trial — Benjamin Saville, Berry Consultants | ||
9:35 AM | Finding Disease-Modifying Therapies for Alzheimer's Disease: A Bayesian Adaptive Development Platform — Melanie Quintana, Berry Consultants ; Scott M. Berry, Berry Consultants ; Mark Fitzgerald, Berry Consultants | ||
9:55 AM | Discussant: Vlad Dragalin, Janssen | ||
10:15 AM | Floor Discussion |
For program information, contact the JSM Registration Department or phone (888) 231-3473.
For Professional Development information, contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
2015 JSM Online Program Home
ASA Meetings Department
732 North Washington Street, Alexandria, VA 22314
(703) 684-1221 • meetings@amstat.org
Copyright © American Statistical Association.